coordinating-multidisciplinary-cancer-care

name	coordinating-multidisciplinary-cancer-care
description	Synthesizes surgical, medical, and radiation oncology inputs into coordinated treatment timelines. Use when coordinating multimodal treatment, scheduling sequential therapies, or managing treatment timelines.
tags	["coordination","oncology","surgical","treatment"]
metadata	{"author":"casemark","practice_areas":["Medical Oncology","Hematology-Oncology","Radiation Oncology"],"document_types":["Coordination Plan"],"skill_modes":["Coordination"]}

Coordinating Multidisciplinary Cancer Care

Synthesizes surgical, medical, and radiation oncology inputs into coordinated treatment timelines.

Why This Skill Exists

Most solid tumors require multimodal therapy — combinations of surgery, systemic therapy, and radiation delivered in a specific sequence with precise timing intervals. A delay of >8 weeks from diagnosis to treatment initiation in head and neck cancer increases mortality. A delay of >120 days from surgery to adjuvant chemotherapy in colorectal cancer diminishes the survival benefit. Uncoordinated care where specialists operate independently results in treatment delays, missed therapy windows, conflicting recommendations, and patient confusion.

CoC Standard 4.3 requires treatment planning within established timeframes. NCCN guidelines specify sequencing and timing for multimodal regimens. The National Quality Forum (NQF) endorsed measures include timeliness of care delivery. Multidisciplinary coordination failures are the leading root cause of treatment delays in cancer care. This skill ensures treatment components are sequenced correctly, timing targets are met, and all specialists are aligned on the care plan.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the cancer diagnosis, stage, and biomarker status? (Default: [VERIFY])
2. What treatment modalities are planned (surgery, chemotherapy, radiation, targeted therapy, immunotherapy)? (Default: per tumor board recommendation)
3. What is the recommended sequencing (neoadjuvant → surgery → adjuvant, concurrent chemoRT, etc.)? (Default: per NCCN guideline)
4. What are the time-critical intervals for this cancer type? (Default: identify from guidelines)
5. Who are the treating specialists (by name) for each modality? (Default: document)
6. Are there patient factors affecting scheduling (comorbidities, travel distance, work, caregiver availability)? (Default: assess)
7. Is the patient enrolled in a clinical trial with protocol-specified timing? (Default: no)
8. Has a patient navigator or care coordinator been assigned? (Default: assess institutional resources)

Documents to Request

• Tumor board recommendation with treatment plan and sequencing
• NCCN guideline timing recommendations for the specific cancer type and stage
• Surgical scheduling availability and pre-operative requirements
• Medical oncology treatment plan with planned start date and cycle schedule
• Radiation oncology consultation with planned simulation and start date
• Pre-treatment workup results (staging, organ function, cardiac clearance)
• Patient insurance authorization status for each modality
• Clinical trial protocol with mandated timelines if applicable

---

Step 1: Map the Treatment Sequence per Evidence-Based Guidelines

Common multimodal sequencing paradigms:

Cancer	Typical Sequence	Critical Timing
Breast (early, neoadjuvant)	Neoadjuvant chemo → Surgery → Adjuvant RT ± hormonal	Surgery within 4–6 weeks after last chemo; RT within 8 weeks of surgery
Breast (adjuvant)	Surgery → Adjuvant chemo → RT → Hormonal	Adjuvant chemo within 4–6 weeks of surgery; RT after chemo completion
Colorectal (rectal, locally advanced)	Neoadjuvant chemoRT → Surgery → Adjuvant chemo	Surgery 6–10 weeks after chemoRT completion; adjuvant chemo within 8 weeks of surgery
Colorectal (colon, stage III)	Surgery → Adjuvant chemo (FOLFOX/CAPOX)	Adjuvant chemo within 4–8 weeks of surgery (benefit diminishes after 8 weeks)
Head & neck (locally advanced)	Concurrent chemoRT (cisplatin + RT)	RT should not be interrupted; total treatment time ≤7 weeks
NSCLC (stage III, unresectable)	Concurrent chemoRT → Durvalumab consolidation	Durvalumab within 1–42 days of chemoRT completion
Esophageal	Neoadjuvant chemoRT → Surgery	Surgery 4–8 weeks after chemoRT
Pancreatic (borderline resectable)	Neoadjuvant chemo ± RT → Restaging → Surgery	Restaging after 2–4 months of neoadjuvant therapy

For each treatment component, document the planned start date, expected duration, and the interval to the next component.

---

Step 2: Identify and Mitigate Time-Critical Gaps

Common causes of treatment delays:

Delay Cause	Mitigation Strategy
Insurance prior authorization	Submit authorization requests immediately upon tumor board recommendation; appeal denials within 24 hours
Incomplete staging workup	Identify all required studies at diagnosis and order simultaneously, not sequentially
Port placement scheduling	Schedule port during surgical consultation, before chemo start date
OR availability for surgery	Book provisional OR date at tumor board; confirm after neoadjuvant response assessment
RT simulation scheduling	Request simulation slot during initial radiation oncology consultation
Molecular testing turnaround	Order comprehensive genomic profiling at diagnosis for disease types requiring biomarker-directed treatment
Specialist referral delays	Direct specialist-to-specialist communication rather than sequential PCP referrals
Patient factors (travel, work)	Involve patient navigator early; assess transportation and logistic barriers

Track each potential delay with a responsible party and resolution date.

---

Step 3: Create the Coordinated Treatment Timeline

Build a visual treatment timeline documenting:

1. Week 0: Diagnosis date and tumor board presentation date
2. Pre-treatment phase: All required workup, authorizations, port placement, dental clearance (for H&N RT), fertility preservation, prehabilitation
3. Treatment Phase 1: First modality with start date, cycle schedule, expected end date
4. Restaging (if applicable): Imaging and assessment between neoadjuvant and surgical phases
5. Treatment Phase 2: Second modality with start date determined by recovery interval
6. Treatment Phase 3: Third modality with start date
7. Post-treatment: First surveillance visit, survivorship care plan delivery

Example timeline — Locally advanced rectal cancer:

• Week 0: Diagnosis, staging, tumor board
• Week 1–2: Pre-treatment workup, port placement, RT simulation
• Week 3–8: Concurrent capecitabine + 50.4 Gy RT (28 fractions)
• Week 14–16: Restaging MRI, interval assessment
• Week 16–18: Surgical resection (TME)
• Week 22–24: Adjuvant chemotherapy initiation (FOLFOX or CAPOX)
• Week 22–46: Adjuvant chemotherapy (4 months total perioperative)

---

Step 4: Establish Communication and Accountability Framework

1. Designate a care coordinator responsible for tracking the treatment timeline
2. Establish communication channels: all treating specialists should receive the complete treatment plan with timeline
3. Create milestone checkpoints:
   • Pre-treatment checklist complete → clear to start treatment
   • Post-neoadjuvant restaging → surgical planning meeting
   • Post-surgery recovery confirmed → medical oncology clearance to start adjuvant
   • Treatment completion → survivorship care plan handoff
4. Patient communication: provide the patient with a written treatment calendar showing appointments, treatment dates, and expected milestones
5. Escalation protocol: define who is contacted when a delay is identified and the maximum acceptable delay before re-evaluation

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Does the treatment sequence match the NCCN guideline recommendation for this cancer type and stage?
2. Are all time-critical intervals identified with target dates and maximum acceptable delays?
3. Is each treatment modality assigned to a named specialist with a planned start date?
4. Have potential delay risks been identified with mitigation strategies?
5. Is the patient informed of the treatment timeline with a written calendar?

---

Quality Audit

• Tumor board recommendation documented with treatment plan and sequencing
• Treatment sequence matches NCCN guideline for the cancer type and stage
• Time-critical intervals identified per evidence-based guidelines
• Each modality has a named treating specialist and planned start date
• Pre-treatment workup checklist complete with all results documented
• Insurance prior authorization obtained or in progress for each modality
• Potential delays identified with mitigation strategies and responsible parties
• Treatment timeline created with milestone checkpoints
• All specialists have received the complete treatment plan
• Patient navigator or care coordinator assigned
• Patient provided written treatment calendar
• Diagnosis-to-treatment interval tracked against benchmark (<4 weeks for most cancers)
• No treatment component scheduled without confirmation from the preceding specialist that the patient is cleared

---

Guidelines

• Treatment delays are the most common preventable quality failure in cancer care — track time from diagnosis to first treatment as a key metric
• The diagnosis-to-treatment interval should not exceed 4 weeks for most solid tumors (exceptions: watchful waiting for low-risk prostate, surveillance for early CLL)
• Never start the next treatment phase without documented clearance from the specialist managing the preceding phase (e.g., surgeon confirms adequate wound healing before starting adjuvant chemo)
• Head and neck radiation should not be interrupted — every day of treatment prolongation beyond the planned schedule reduces local control by approximately 1.4% per day
• For concurrent chemoradiation, chemotherapy and radiation must start simultaneously — do not delay radiation to "complete a full cycle" of chemotherapy first
• Molecular testing should be ordered at diagnosis, not after treatment failure — turnaround time can be 2–3 weeks and delays targeted therapy initiation
• Fertility preservation counseling must occur before treatment initiation — it cannot be done after gonadotoxic therapy begins
• Patient navigation reduces treatment delays by 30–50% in underserved populations — advocate for navigator assignment for complex multimodal plans